Teriflunomide

SKU: orb1299732

Description

Teriflunomide (A 77-1726) is the primary active metabolite derived from leflunomide, a drug approved for treating rheumatoid arthritis and multiple sclerosis. This small molecule inhibitor of dihydroorotate dehydrogenase is widely used in immunology and neurology research, facilitating both in vitro cellular studies and in vivo disease modeling.

Research Area

Metabolism Research

Key Properties

• CAS Number: 163451-81-8
• MW: 270.21
• Purity: 99.95% (May vary between batches)
• Formula: C₁₂H₉F₃N₂O₂
• SMILES: C(F)(F)(F)C1=CC=C(NC(/C(=C(/C)\O)/C#N)=O)C=C1
• Target: Others,Drug Metabolite
• Solubility: DMSO:29.41 mg/mL (108.84 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (7.4 mM)

Bioactivity

• In Vitro:
  Teriflunomide primarily acts as an inhibitor of dihydroorotate dehydrogenase (DHODH), a key mitochondrial enzyme involved in the de novo synthesis of pyrimidines in rapidly proliferating cells. By reducing the activity of high-avidity proliferating T lymphocytes and B lymphocytes, teriflunomide likely attenuates the inflammatory response to autoantigens in MS. Notably, DHODH blockade does not affect resting or homeostatically proliferating hematopoietic cell lines, as pyrimidine pools in these cells can be generated through an alternate 'salvage pathway,' which is independent of DHODH. Thus, teriflunomide can be considered a cytostatic rather than a cytotoxic drug to leukocytes .

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

A77 1726, A 77-1726, Inhibitor, inhibit, Teriflunomide

Compound Identifiers

PubChem CID

54684141